Group 1 - Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies, currently trading on NASDAQ under the symbol LINE [1] - Scotiabank has set a price target of $39 for LINE, indicating a potential upside of approximately 7.04% from its current trading price of $36.55 [1][5] - The company has achieved a significant milestone by receiving a novel induced pluripotent stem cell (iPSC) line with hypoimmunity edits in collaboration with Factor Bioscience Inc., which is crucial for developing allogeneic cell therapies [2][5] Group 2 - The current trading price of LINE is $36.55, reflecting a slight decrease of 0.02 or approximately -0.05%, with fluctuations between a low of $35.70 and a high of $37.08 today [3] - Over the past year, LINE has experienced a high of $62.30 and a low of $32.45, indicating significant market volatility [3][5] - Lineage's market capitalization is approximately $8.35 billion, with a trading volume of 365,212 shares, suggesting moderate investor interest and activity [4]